Dysmenorrhea

5
Pipeline Programs
4
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
4 programs
1
1
1
Naproxen Sodium,Phase 41 trial
EE20/DRSPPhase 31 trial
DRSP 3 mg/EE 20 µgPhase 2/31 trial
LEPN/A5 trials
Active Trials
NCT04607382Completed397Est. Jun 2021
NCT04534452Completed347Est. Jun 2012
NCT01413958Completed575Est. Oct 2011
+5 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Meloxicam 7.5 mgPhase 21 trial
Active Trials
NCT02183025Completed337
Teva
TevaIsrael - Petach Tikva
1 program
1
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tabletsPhase 22 trials
Active Trials
NCT00196313Completed95Est. Oct 2008
NCT00196365Completed97Est. Jul 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerNaproxen Sodium,
BayerEE20/DRSP
BayerLEP
BayerLEP
BayerLEP
Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
BayerDRSP 3 mg/EE 20 µg
BayerLEP
Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Boehringer IngelheimMeloxicam 7.5 mg
BayerLEP
BayerLEP

Clinical Trials (12)

Total enrollment: 3,363 patients across 12 trials

NCT03448536BayerNaproxen Sodium,

A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Start: Apr 2018Est. completion: Sep 2018201 patients
Phase 4Completed
NCT02617537BayerEE20/DRSP

To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Start: Jan 2016Est. completion: Oct 20170
Phase 3Withdrawn
NCT04534452BayerLEP

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

Start: May 2012Est. completion: Jun 2012347 patients
Phase 3Completed
NCT01413958BayerLEP

Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)

Start: Aug 2011Est. completion: Oct 2011575 patients
Phase 3Completed
NCT00976209BayerLEP

Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)

Start: Aug 2009Est. completion: Nov 2009331 patients
Phase 3Completed
NCT00196365Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Start: Jan 2005Est. completion: Jul 200797 patients
Phase 3Completed
NCT00461305BayerDRSP 3 mg/EE 20 µg

Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea

Start: Feb 2007Est. completion: Aug 2009420 patients
Phase 2/3Completed
NCT01330017BayerLEP

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

Start: Mar 2011Est. completion: Jun 2011539 patients
Phase 2Completed
NCT00196313Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Start: May 2005Est. completion: Oct 200895 patients
Phase 2Completed
NCT02183025Boehringer IngelheimMeloxicam 7.5 mg

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Start: Jan 1998337 patients
Phase 2Completed
NCT01354418BayerLEP

Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)

Start: May 2011Est. completion: Jul 201124 patients
Phase 1Completed
NCT04607382BayerLEP

Survey on Menstrual Symptoms, Health Related Quality of Life and Work Productivity in Patients Suffering From Pain During Menstruation (Dysmenorrhea) in Japan

Start: Sep 2020Est. completion: Jun 2021397 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space